Kyn Therapeutics inks $49 mln Series A
Cambridge, Massachusetts-based Kyn Therapeutics, a provider of new immunometabolism therapies for treating cancer, has secured $49 million in Series A funding. The investors were Atlas Venture and OrbiMed.
14 December 2017•1 min read
